GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK.
Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, is an antidiabetic drug. It has been shown to improve the Psoriasis Area and Severity Index (PASI) in patients with type 2 diabetes and psoriasis in clinical practice, but the mechanism remains somewhat unclear. We used lipopolysaccharides (LPS) to induce inflammatory response in keratinocytes and explore the mechanism. The HaCat cells were incubated with LPS for 16 h and then were treated with liraglutide for 30 min. Cell viability was testing by CCK-8 assay. GLP-1Rs and intracellular signaling pathways were identified by Western blot. The migration of macrophage was detecting by trans-well assay. Liraglutide decreased cell viability in the HaCat cells. Liraglutide restrained the migration of macrophage to the HaCat cells. LPS elevated not only the protein abundance of phospho-IKKα/β S176/S180, phospho-NF-κB p65, phospho-JAK2, phospho-STAT3 and SOCS3, but also the levels of TNF-α and IL-6 in the HaCat cells. These effects of LPS were reversed by liraglutide. In addition, liraglutide increased phosphorylation of AMPK. The AMPK inhibitor Compound (CC) impaired liraglutide-inhibited p-NF-κB p65 and p-STAT3. GLP-1 impaired keratinocytes inflammatory signals by activating AMPK and restrained macrophage migration.